20 articles for JD Katz
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation.
Merck
Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.
Merck
Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.
Merck
Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.
Merck Research Laboratories
Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators.
Merck
Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors.
Merck
Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow.
Merck
Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability.
TBA
Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
Celgene Quanticel Research
N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
Bayer Pharma Aktiengesellschaft
1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives
Actelion Pharmaceuticals
Hydroxylated aminotriazole derivatives as ALX receptor agonists
Actelion Pharmaceuticals
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Abbvie